297 related articles for article (PubMed ID: 6725557)
1. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
[TBL] [Abstract][Full Text] [Related]
2. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
3. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
[TBL] [Abstract][Full Text] [Related]
4. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
6. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Zamarron C; Lijnen HR; Van Hoef B; Collen D
Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
8. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
Rijken DC; Binnema DJ; Los P
Thromb Res; 1986 Jun; 42(6):761-8. PubMed ID: 2425448
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
Gurewich V; Pannell R
Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
[TBL] [Abstract][Full Text] [Related]
10. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
11. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Holmes WE; Collen D
J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
[TBL] [Abstract][Full Text] [Related]
13. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
Liu JN; Gurewich V
Blood; 1993 Feb; 81(4):980-7. PubMed ID: 8428004
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.
Kasai S; Arimura H; Nishida M; Suyama T
Cell Struct Funct; 1985 Jun; 10(2):151-9. PubMed ID: 3924420
[TBL] [Abstract][Full Text] [Related]
15. New approaches to thrombolytic therapy.
Collen D; Lijnen HR
Arteriosclerosis; 1984; 4(6):579-85. PubMed ID: 6439177
[TBL] [Abstract][Full Text] [Related]
16. The pH dependence of the binding of pro-urokinase to fibrin/celite.
Pannell R; Angles-Cano E; Gurewich V
Thromb Haemost; 1990 Dec; 64(4):556-8. PubMed ID: 2128139
[TBL] [Abstract][Full Text] [Related]
17. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
20. Fibrin activatable urokinase (FA-UK): a latent form of UK found in urine related to a complex with an inhibitor/fibrin-interacting cofactor.
Dwivedi C; Pannell R; Gurewich V
Thromb Res; 1988 Jul; 51(2):197-208. PubMed ID: 3055414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]